Next News Japan The Japanese government has also revised the medical device regulatory review process to shorten and standardize the review time for medical device approval which will help foreign medical device companies to get their products on the Japanese market sooner. CardioComm itself has almost 20 years of Class II medical device clearances with Health Canada and the FDA and will have ISO 13485:2016 under MDSAP which will facilitate such regulatory review.
Read more at https://www.stockhouse.com/news/press-releases/2018/02/22/cardiocomm-solutions-participates-in-ontario-trade-mission-to-japan-and-korea#18MWAlByTcxV1MTW.99
The Japanese government has also revised the medical device regulatory review process to shorten and standardize the review time for medical device approval which will help foreign medical device companies to get their products on the Japanese market sooner. CardioComm itself has almost 20 years of Class II medical device clearances with Health Canada and the FDA and will have ISO 13485:2016 under MDSAP which will facilitate such regulatory review.
Read more at https://www.stockhouse.com/news/press-releases/2018/02/22/cardiocomm-solutions-participates-in-ontario-trade-mission-to-japan-and-korea#18MWAlByTcxV1MTW.99
The Japanese government has also revised the medical device regulatory review process to shorten and standardize the review time for medical device approval which will help foreign medical device companies to get their products on the Japanese market sooner. CardioComm itself has almost 20 years of Class II medical device clearances with Health Canada and the FDA and will have ISO 13485:2016 under MDSAP which will facilitate such regulatory review.
Read more at https://www.stockhouse.com/news/press-releases/2018/02/22/cardiocomm-solutions-participates-in-ontario-trade-mission-to-japan-and-korea#18MWAlByTcxV1MTW.99
The medical market in Japan provides a large opportunity to introduce North American standards for cardiac outpatient monitoring. In Japan there are approximately 100,955 medical clinics and 1.5 million hospital beds in 8,480 hospitals (2015 statistics,
www.mhlw.go.jp). Directives issued under the Japanese Health, Labor and Welfare Ministry are introducing new medical fee reimbursements related to the implementation of telemedicine platforms with an effective date of April 1, 2018. The new reimbursement fees will support Japan's efforts to encourage doctors to offer medical counseling over the internet. Of specific relevance to CardioComm is the implementation of a new telemedicine fee for mobile ECG monitoring at a value of 1500 JPY per ECG (approximately Cdn$18.29).
Read more at https://www.stockhouse.com/news/press-releases/2018/03/05/cardiocomm-solutions-trade-mission-to-japan-and-korea-yields-25-meetings-with#5Lqbl8zf9PjlGEv4.99 The medical market in Japan provides a large opportunity to introduce North American standards for cardiac outpatient monitoring. In Japan there are approximately 100,955 medical clinics and 1.5 million hospital beds in 8,480 hospitals (2015 statistics,
www.mhlw.go.jp). Directives issued under the Japanese Health, Labor and Welfare Ministry are introducing new medical fee reimbursements related to the implementation of telemedicine platforms with an effective date of April 1, 2018. The new reimbursement fees will support Japan's efforts to encourage doctors to offer medical counseling over the internet. Of specific relevance to CardioComm is the implementation of a new telemedicine fee for mobile ECG monitoring at a value of 1500 JPY per ECG (approximately Cdn$18.29).
Read more at https://www.stockhouse.com/news/press-releases/2018/03/05/cardiocomm-solutions-trade-mission-to-japan-and-korea-yields-25-meetings-with#5Lqbl8zf9PjlGEv4.99 The medical market in Japan provides a large opportunity to introduce North American standards for cardiac outpatient monitoring. In Japan there are approximately 100,955 medical clinics and 1.5 million hospital beds in 8,480 hospitals (2015 statistics,
www.mhlw.go.jp). Directives issued under the Japanese Health, Labor and Welfare Ministry are introducing new medical fee reimbursements related to the implementation of telemedicine platforms with an effective date of April 1, 2018. The new reimbursement fees will support Japan's efforts to encourage doctors to offer medical counseling over the internet. Of specific relevance to CardioComm is the implementation of a new telemedicine fee for mobile ECG monitoring at a value of 1500 JPY per ECG (approximately Cdn$18.29).
Read more at https://www.stockhouse.com/news/press-releases/2018/03/05/cardiocomm-solutions-trade-mission-to-japan-and-korea-yields-25-meetings-with#5Lqbl8zf9PjlGEv4.99 The medical market in Japan provides a large opportunity to introduce North American standards for cardiac outpatient monitoring. In Japan there are approximately 100,955 medical clinics and 1.5 million hospital beds in 8,480 hospitals (2015 statistics,
www.mhlw.go.jp). Directives issued under the Japanese Health, Labor and Welfare Ministry are introducing new medical fee reimbursements related to the implementation of telemedicine platforms with an effective date of April 1, 2018. The new reimbursement fees will support Japan's efforts to encourage doctors to offer medical counseling over the internet. Of specific relevance to CardioComm is the implementation of a new telemedicine fee for mobile ECG monitoring at a value of 1500 JPY per ECG (approximately Cdn$18.29).
Read more at https://www.stockhouse.com/news/press-releases/2018/03/05/cardiocomm-solutions-trade-mission-to-japan-and-korea-yields-25-meetings-with#5Lqbl8zf9PjlGEv4.99 The Japanese government has also revised the medical device regulatory review process to shorten and standardize the review time for medical device approval which will help foreign medical device companies to get their products on the Japanese market sooner. CardioComm itself has almost 20 years of Class II medical device clearances with Health Canada and the FDA and will have ISO 13485:2016 under MDSAP which will facilitate such regulatory review.
Read more at https://www.stockhouse.com/news/press-releases/2018/02/22/cardiocomm-solutions-participates-in-ontario-trade-mission-to-japan-and-korea#R04rHl8syTFGKmKh.99
The Japanese government has also revised the medical device regulatory review process to shorten and standardize the review time for medical device approval which will help foreign medical device companies to get their products on the Japanese market sooner. CardioComm itself has almost 20 years of Class II medical device clearances with Health Canada and the FDA and will have ISO 13485:2016 under MDSAP which will facilitate such regulatory review.